[
  {
    "ts": null,
    "headline": "Zimmer Biomet’s Q1 Earnings Call: Our Top 5 Analyst Questions",
    "summary": "Zimmer Biomet’s first quarter results were met with a sharp negative reaction from the market, as investors weighed both the modest revenue growth and a lowered outlook for the year. Management attributed the quarter’s performance to strong adoption of new hip products in the U.S. and sustained mid-single-digit growth in its S.E.T. (Sports Medicine, Extremities and Trauma) segment, despite facing a headwind from one less selling day. CEO Ivan Tornos highlighted the impact of Zimmer Biomet’s \"mag",
    "url": "https://finnhub.io/api/news?id=5861fc35f4fd7914110922201426634fd89c367bdabeb890071058f1a190a342",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750974461,
      "headline": "Zimmer Biomet’s Q1 Earnings Call: Our Top 5 Analyst Questions",
      "id": 135586827,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZBH",
      "source": "Yahoo",
      "summary": "Zimmer Biomet’s first quarter results were met with a sharp negative reaction from the market, as investors weighed both the modest revenue growth and a lowered outlook for the year. Management attributed the quarter’s performance to strong adoption of new hip products in the U.S. and sustained mid-single-digit growth in its S.E.T. (Sports Medicine, Extremities and Trauma) segment, despite facing a headwind from one less selling day. CEO Ivan Tornos highlighted the impact of Zimmer Biomet’s \"mag",
      "url": "https://finnhub.io/api/news?id=5861fc35f4fd7914110922201426634fd89c367bdabeb890071058f1a190a342"
    }
  }
]